Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, and 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth

NCT02428491 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT02428491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, and 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 3
Overall status
Completed
Start date
April 20, 2015
Completion date
January 11, 2017
Enrollment
354 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, hepatitis b, pertussis, poliomyelitis, tetanus